Procept Biorobotics Corp
NASDAQ:PRCT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
P
|
Procept Biorobotics Corp
NASDAQ:PRCT
|
US |
Procept Biorobotics Corp
Procept BioRobotics makes robotic medical devices for treating enlarged prostate, a common condition in older men. Its main product is the AQUABEAM system, which helps urologists remove extra prostate tissue using a precise waterjet guided by imaging and robotics. The company’s tools are used in hospitals and outpatient surgery centers where doctors perform these procedures. The business makes money in two main ways: it sells the robotic system to healthcare providers, and it also sells disposable parts, service, and support tied to each procedure. That creates a repeat revenue stream after the initial equipment sale. Its main customers are urologists, hospitals, and surgery centers that want a treatment option that can be less manual and more precise than older surgical methods. What makes Procept different is that it is not just another medical device seller; it sits between surgical robotics and urology. Instead of broad surgical use, it focuses on one specific procedure area and designs both the machine and the treatment workflow around it. That narrow focus gives the company a clear role in the care pathway for prostate enlargement treatments.
Procept BioRobotics makes robotic medical devices for treating enlarged prostate, a common condition in older men. Its main product is the AQUABEAM system, which helps urologists remove extra prostate tissue using a precise waterjet guided by imaging and robotics. The company’s tools are used in hospitals and outpatient surgery centers where doctors perform these procedures.
The business makes money in two main ways: it sells the robotic system to healthcare providers, and it also sells disposable parts, service, and support tied to each procedure. That creates a repeat revenue stream after the initial equipment sale. Its main customers are urologists, hospitals, and surgery centers that want a treatment option that can be less manual and more precise than older surgical methods.
What makes Procept different is that it is not just another medical device seller; it sits between surgical robotics and urology. Instead of broad surgical use, it focuses on one specific procedure area and designs both the machine and the treatment workflow around it. That narrow focus gives the company a clear role in the care pathway for prostate enlargement treatments.
Revenue: PROCEPT BioRobotics reported first-quarter revenue of $83.1 million, up 20% year over year, with U.S. revenue of $72 million and international revenue up 25%.
Pricing: The company said pricing was stronger than expected, with U.S. Hydros system ASP at about $485,000, an all-time high and up 14% from Q4 2025.
Margins: Gross margin reached 65% in Q1, matching the full-year target and improving from 61% in Q4, helped by pricing, cost discipline and mix.
Operations: Management said the commercial reset caused some short-term disruption, but procedures were broadly in line with expectations and benefits should build in the second half.
Outlook: The company kept full-year revenue guidance at $390 million to $410 million and Q2 revenue guidance at $91 million to $95 million, while saying confidence in the full-year plan has increased.
Clinical momentum: PROCEPT highlighted a strong EAU guideline update for Aquablation, first international Hydros sales in the U.K., FDA clearance for FirstAssist AI, and WATER IV enrollment expected to finish by the end of May.
